Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Standard BioTools Inc. Market Cap
Based on ratings from 3 stock analysts, the Standard BioTools Inc. stock price is expected to increase by 52.64% in 12 months. This is calculated by using the average 12-month stock price forecast for Standard BioTools Inc.. The lowest target is $2.5 and the highest is $4. Please note analyst price targets are not guaranteed and could be missed completely.
Standard BioTools Inc. has a total of 3 Wall St Analyst ratings. There are 3 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Standard BioTools Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of LAB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Daniel Brennan TD Cowen | Buy | $2.5 | Maintains | Oct 31, 2024 |
| Daniel Brennan TD Cowen | Buy | $2.75 | Maintains | Aug 1, 2024 |
| Daniel Brennan TD Cowen | Buy | $3.5 | Initiates | Apr 16, 2024 |
| Matthew Stanton Jefferies | Buy | $3.25 | Initiates | Apr 4, 2024 |
| Paul Knight Keybanc | Overweight | $4 | Initiates | Jul 12, 2023 |
UBS | Buy | Maintains | Aug 27, 2020 | |
UBS | Buy | Maintains | Aug 10, 2020 | |
Janney Montgomery Scott | Neutral | Downgrade | Nov 6, 2019 | |
UBS | Buy | Upgrade | Oct 18, 2019 | |
UBS | Neutral | Initiates | Mar 15, 2019 | |
BTIG | Buy | Initiates | Mar 14, 2019 | |
Janney Montgomery Scott | Buy | Upgrade | Jan 3, 2019 | |
Piper Sandler | Overweight | Upgrade | Nov 2, 2018 | |
Mizuho | Buy | Upgrade | Feb 5, 2016 | |
Deutsche Bank | Buy | Maintains | Feb 5, 2016 | |
Cowen & Co. | Market Perform | Downgrade | Jan 20, 2016 | |
Deutsche Bank | Buy | Initiates | Jan 6, 2016 | |
Avondale Partners | Market Outperform | Initiates | Jan 6, 2016 | |
Cantor Fitzgerald | Buy | Upgrade | Nov 2, 2015 | |
Cantor Fitzgerald | Buy | Upgrade | Oct 30, 2015 |
When did it IPO
2022
Staff Count
534
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Michael Egholm Ph.D.
Market Cap
$685.0M
In 2023, LAB generated $106.3M in revenue, which was a increase of 8.57% from the previous year. This can be seen as a signal that LAB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Standard BioTools Inc. appointed Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim has nearly 30 years of experience in healthcare and life sciences.
Why It Matters - The appointment of a seasoned CFO like Alex Kim, with extensive industry experience, signals potential for stronger financial management and strategic growth, impacting investor confidence and stock performance.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Standard BioTools Inc. will hold its Q3 2024 earnings conference call on October 30, 2024, at 4:30 PM ET, featuring CEO Michael Egholm and COO Alex Kim.
Why It Matters - Standard BioTools' Q3 earnings call will provide insights into financial performance and strategic direction, critical for assessing investment potential and market confidence.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Standard BioTools Inc. (NASDAQ: LAB) announced its unaudited interim financial results for Q3 2024, ended September 30. Further details on performance were not provided in the excerpt.
Why It Matters - Unaudited interim financial results can indicate a company's performance trends, impacting stock prices and investor sentiment based on revenue, expenses, and growth potential.
Wed, 30 Oct 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Standard BioTools (LAB) reported a quarterly loss of $0.05 per share, beating the Zacks Consensus Estimate of $0.08, and improving from a loss of $0.15 per share a year earlier.
Why It Matters - Standard BioTools' smaller-than-expected loss indicates improving financial health, potentially boosting investor confidence and affecting stock performance positively.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Standard BioTools Inc. (NASDAQ: LAB) will present at the UBS Global Healthcare Conference on November 12, 2024, at 1:15 p.m. with CEO Michael Egholm, PhD, participating.
Why It Matters - Standard BioTools' participation in key investor conferences highlights its visibility and engagement with the investment community, potentially impacting stock interest and market sentiment.
Wed, 16 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Standard BioTools Inc. (NASDAQ: LAB) will release its third quarter 2024 financial results on October 30, 2024, after market close.
Why It Matters - The upcoming financial results announcement could impact Standard BioTools' stock price, providing insights into its performance and future outlook.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
